Science Pool

Evotec spin-off Topas Therapeutics extends Series B, raising total of €40 Million (~$48 Million) in this Round

Evotec spin-off company Topas Therapeutics GmbH (“Topas”), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional € 18 m (~$ 22 m) raised, bringing the total for this financing to € 40 m. All of Topas’ existing investors participated in the extension.
Read More

Twitter
LinkedIn
Email